Celator Pharmaceuticals (CPXX) 10-Q 10 May 16 2016 Q1 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	3 Months Ended
	Mar. 31, 2016	May. 06, 2016
Document Information [Line Items]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Mar. 31, 2016
Document Fiscal Year Focus	2,016
Document Fiscal Period Focus	Q1
Entity Registrant Name	Celator Pharmaceuticals Inc
Entity Central Index Key	1,327,467
Current Fiscal Year End Date	--12-31
Entity Filer Category	Smaller Reporting Company
Trading Symbol	CPXX
Entity Common Stock, Shares Outstanding		42,470,256

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($)	Mar. 31, 2016	Dec. 31, 2015
Current assets:
Cash and cash equivalents	$ 67,541,467	$ 23,253,328
Restricted cash	150,921	149,017
Other receivables	116,859	74,244
Prepaid expenses and deposits	329,800	421,491
Other current assets	407,043	414,904
Total current assets	68,546,090	24,312,984
Property and equipment, net	816,438	861,490
Other assets	43,024	43,998
Total assets	69,405,552	25,218,472
Current liabilities:
Current portion of debt	436,690	5,378,134
Accounts payable	394,369	778,360
Accrued liabilities	2,081,544	2,377,713
Current portion of deferred revenue	0	45,249
Total current liabilities	2,912,603	8,579,456
Other liabilities	1,024,177	1,026,993
Loans payable	12,837,810	9,081,110
Total liabilities	16,774,590	18,687,559
Stockholders' equity
Preferred stock Authorized 20,000,000 shares, par value $0.001	0	0
Common stock Authorized 200,000,000 shares, par value $0.001 Issued and outstanding 41,222,270 and 34,944,150 shares as of March 31, 2016 and December 31, 2015, respectively	41,222	34,944
Warrants	1,083,193	1,083,193
Additional paid-in capital	226,856,737	175,229,643
Accumulated other comprehensive loss	(1,133,266)	(1,133,266)
Accumulated deficit	(174,216,924)	(168,683,601)
Total stockholders' equity	52,630,962	6,530,913
Total liabilities and stockholders' equity	$ 69,405,552	$ 25,218,472

Consolidated Balance Sheets _Pa

Consolidated Balance Sheets [Parenthetical] - $ / shares	Mar. 31, 2016	Dec. 31, 2015
Preferred Stock, Shares Authorized	20,000,000	20,000,000
peferred stock, par valur (in dollars per share)	$ 0.001	$ 0.001
Common stock, authorized shares	200,000,000	200,000,000
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, issued shares	41,222,270	34,944,150
Common stock, outstanding shares	41,222,270	34,944,150

Consolidated Statements of Loss

Consolidated Statements of Loss - USD ($)	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Expenses
Research and development	$ 2,689,189	$ 2,708,011
Leukemia & Lymphoma Society funding	(145,249)	(135,747)
General and administrative	2,468,648	1,761,449
Amortization and depreciation	48,347	48,928
Operating loss	(5,060,935)	(4,382,641)
Other income (expenses)
Foreign exchange gain (loss)	(15,984)	9,639
Interest and miscellaneous income	2,329	3,141
Interest expense	(458,733)	(341,122)
Net loss	$ (5,533,323)	$ (4,710,983)
Net loss per share
Basic and diluted (in dollars per share)	$ (0.16)	$ (0.14)
Weighted average of common shares outstanding
Basic and diluted (in shares)	35,400,496	33,704,889

Consolidated Statements of Stoc

Consolidated Statements of Stockholders' Equity - 3 months ended Mar. 31, 2016 - USD ($)	Total	Common Stock [Member]	Warrants [Member]	Additional Paid-In Capital [Member]	Accumulated Other Comprehensive Loss [Member]	Accumulated Deficit [Member]
Balance at Dec. 31, 2015	$ 6,530,913	$ 34,944	$ 1,083,193	$ 175,229,643	$ (1,133,266)	$ (168,683,601)
Balance (in shares) at Dec. 31, 2015		34,944,150
Issuance of shares from exercise of stock options and warrants	295,640	$ 324	0	295,316	0	0
Issuance of shares from exercise of stock options and warrants (in share)		324,220
Issued for cash, net of stock issuance costs	50,396,400	$ 5,954	0	50,390,446	0	0
Issued for cash, net of stock issuance costs (in share)		5,953,900
Stock-based compensation	576,070	$ 0	0	576,070	0	0
Stock options granted in payment of accrued bonuses	365,262	0	0	365,262	0	0
Net loss for the period	(5,533,323)	0	0	0	0	(5,533,323)
Balance at Mar. 31, 2016	$ 52,630,962	$ 41,222	$ 1,083,193	$ 226,856,737	$ (1,133,266)	$ (174,216,924)
Balance (in shares) at Mar. 31, 2016		41,222,270

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($)	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Operating activities
Net loss	$ (5,533,323)	$ (4,710,983)
Adjustments to reconcile net loss to net cash used in operating activities
Amortization and depreciation	48,347	48,928
Non-cash stock-based compensation expense	576,070	359,200
Non-cash financing costs	112,117	94,664
Changes in operating assets and liabilities
Other receivables	(42,362)	(4,864)
Prepaid expenses and deposits	94,826	79,617
Restricted cash	(6)	(8)
Other current assets	7,861	16,266
Other assets	1,012	0
Accounts payable	(385,118)	46,113
Accrued liabilities	62,979	(285,171)
Deferred rent liability	(2,816)	(2,218)
Deferred revenue	(45,249)	(135,746)
Cash used in operating activities	(5,105,662)	(4,494,202)
Investing activities
Purchase of property and equipment	(3,295)	(17,938)
Cash used in investing activities	(3,295)	(17,938)
Financing activities
Proceeds from issuance of common stock and stock options and warrants exercised	51,105,723	0
Payment of share issuance costs	(413,357)	0
Proceeds from loans payable	0	5,000,000
Repayments of loans payable	(1,296,861)	0
Cash provided by financing activities	49,395,505	5,000,000
Effect of foreign exchange rate changes	1,591	(3,825)
Net change in cash	44,288,139	484,035
Cash and cash equivalents, beginning of period	23,253,328	32,413,777
Cash and cash equivalents, end of period	67,541,467	32,897,812
Supplemental disclosure of cash flow information
Interest paid	356,166	243,750
Stock options granted in payment of accrued bonuses	365,262	0
Common stock issued in payment of accrued bonuses	0	168,843
Warrants issued in connection with debt issuance costs	$ 0	$ 76,897

Nature of Business and Liquidit

Nature of Business and Liquidity	3 Months Ended
	Mar. 31, 2016
Accounting Policies [Abstract]
Nature of Operations [Text Block]	1. Nature of Business and Liquidity Celator Pharmaceuticals, Inc. is an oncology-focused biopharmaceutical company that is transforming the science of combination therapy, and developing products to improve patient outcomes in cancer. Our proprietary technology platform, CombiPlex®, enables the rational design and rapid evaluation of optimized combinations incorporating traditional chemotherapies as well as molecularly targeted agents to deliver enhanced anti-cancer activity. CombiPlex addresses several fundamental shortcomings of conventional combination regimens, as well as the challenges inherent in combination drug development, by identifying the most effective synergistic molar ratio of the drugs being combined in vitro, and fixing this ratio in a nano-scale drug delivery complex to maintain the optimized combination after administration and ensure its exposure to the tumor. Our lead product is VYXEOS TM The Company has incurred recurring losses and negative cash flows from operations since inception. As of March 31, 2016, the Company had an accumulated deficit of $ 174.2 67.5 The Company is subject to those risks associated with any specialty pharmaceutical company that has substantial expenditures for research and development. There can be no assurance that the Company’s research and development projects will be successful, that products developed will obtain necessary regulatory approval, or that any approved product will be commercially viable. Substantial additional financing will be needed by the Company to fund its operations and to commercialize its product candidates. There is no assurance that such financing will be available when needed or on acceptable terms. In addition, the Company operates in an environment of rapid technological change and is largely dependent on the services of its employees and consultants.

Summary of Significant Accounti

Summary of Significant Accounting Policies	3 Months Ended
	Mar. 31, 2016
Accounting Policies [Abstract]
Significant Accounting Policies [Text Block]	2. Summary of Significant Accounting Policies The accompanying unaudited consolidated financial statements and related disclosures have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”) and should be read in conjunction with the consolidated financial statements and notes included in Company’s Annual Report on Form 10-K for the year ended December 31, 2015. Certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”) have been omitted. In the opinion of management of the Company, the interim consolidated financial statements reflect all adjustments considered necessary for a fair presentation of the financial position, operating results and cash flows of the interim periods. All such adjustments are of a normal, recurring nature. The results of operations for the interim periods are not necessarily indicative of the results of operations to be expected for the full year. : The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries, Celator Pharmaceuticals Corp. (“CPC”) and Celator UK Ltd. All intercompany transactions have been eliminated. The preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of expenses during the reporting period. Actual results may differ from those estimates. Significant areas requiring management estimates in the preparation of these consolidated financial statements include, amongst other things, assessment of other receivables, accrued liabilities, impairment and amortization of property and equipment, valuation allowance for deferred income taxes, valuation of stock-based compensation and contingencies. New Accounting Pronouncements Adopted: Deferred As Reported Financing Costs Adjusted December 31, 2015 Reclassification December 31, 2015 Assets Other assets $ 460,710 $ (416,712) $ 43,998 Total assets $ 25,635,184 $ (416,712) $ 25,218,472 Loans payable $ 9,497,822 $ (416,712) $ 9,081,110 Total liabilities 19,104,271 (416,712) 18,687,559 Total liabilities and stockholders' equity $ 25,635,184 $ (416,712) $ 25,218,472 All other new guidance that became effective during the reported period did not have a material impact on the Company’s consolidated financial statements. In February 2016, the FASB issued comprehensive new guidance about leases. Under the new guidance, most leases will be recognized on an entity’s balance sheet as liabilities with corresponding right-of-use assets. The new guidance is effective for interim and annual period in fiscal years beginning after December 15, 2018, with early adoption permitted. The standard must be adopted using a modified retrospective approach. We have not yet evaluated the impact of this new pronouncement. In November 2015, the FASB issued guidance which requires entities with a classified balance sheet to present all deferred tax assets and liabilities as noncurrent. The guidance is effective for public business entities for interim and annual periods in fiscal years beginning after December 15, 2016. This guidance is not expected to have a material impact on the Company’s consolidated financial position, results of operations or cash flows. In August 2014, the FASB issued guidance on management’s responsibility in evaluating whether there is substantial doubt about a company’s ability to continue as a going concern and about related footnote disclosures. For each reporting period, management will be required to evaluate whether there are conditions or events that raise substantial doubt about a company’s ability to continue as a going concern within one year from the date the financial statements are issued. The guidance is effective for the annual period ending after December 15, 2016, and for annual periods and interim periods thereafter.

Fair Value Measurements

Fair Value Measurements	3 Months Ended
	Mar. 31, 2016
Fair Value Disclosures [Abstract]
Fair Value Disclosures [Text Block]	3. Fair Value Measurements Financial instruments of the Company consist of cash deposits, money market investments, other receivables, accounts payable, certain accrued liabilities and debt. The carrying value of these financial instruments generally approximates fair value due to their short-term nature. The Company believes that the current carrying amount of its long-term debt approximates fair value because interest rate on this instrument is similar to rates that the Company would be able to receive for similar instruments of comparable maturity. FASB Accounting Standards Codification (“ASC”) Topic 820, Fair Value Measurements Level 1 applies to assets or liabilities for which there are quoted prices in active markets for identical assets or liabilities. Level 2 applies to assets or liabilities for which there are inputs, other than quoted prices included within Level 1, that are observable for the asset or liability, such as: quoted prices for similar assets or liabilities in active markets; quoted prices for identical assets or liabilities in markets with insufficient volume or infrequent transactions (less active markets); or model-derived valuations in which significant inputs are observable or can be derived principally from, or corroborated by, observable market data. Level 3 applies to assets or liabilities for which there are unobservable inputs to the valuation methodology that are significant to the measurement of the fair value of the assets or liabilities. ASC 820 requires disclosures about transfers into and out of Levels 1 and 2 and separate disclosures about purchases, sales, issuances, and settlements relating to Level 3 measurements. It also clarifies existing fair value disclosures regarding the level of disaggregation and the inputs and valuation techniques used to measure fair value. The Company recognizes transfers between input levels as of the actual date of event. Fair Value (Level 1) (Level 2) (Level 3) March 31, 2016 Assets: Money Market Fund $ 17,194,140 $ 17,194,140 $ - $ - December 31, 2015 Assets: Money Market Fund $ 22,162,678 $ 22,162,678 $ - $ -

Other Current Assets

Other Current Assets	3 Months Ended
	Mar. 31, 2016
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
Other Current Assets [Text Block]	4. Other Current Assets March 31, 2016 December 31, 2015 Clinical trial materials $ 407,043 $ 414,904

Property and Equipment

Property and Equipment	3 Months Ended
	Mar. 31, 2016
Property Plant And Equipment [Abstract]
Property Plant And Equipment Disclosure [Text Block]	5. Property and Equipment Property and equipment as of March 31, 2016 and December 31, 2015, including assets held under capital lease, consists of the following: March 31, 2016 December 31, 2015 Computer and equipment $ 118,935 $ 117,135 Furniture and office equipment 73,863 73,863 Laboratory equipment 1,754,608 1,754,608 Capital lease equipment 155,524 155,524 Leaseholds 56,227 54,732 2,159,157 2,155,862 Less: Accumulated depreciation (1,342,719) (1,294,372) $ 816,438 $ 861,490 During the three months ended March 31, 2016 and March 31, 2015, depreciation and amortization expense was $ 48,347 48,928

Accrued Liabilities

Accrued Liabilities	3 Months Ended
	Mar. 31, 2016
Payables And Accruals [Abstract]
Accounts Payable And Accrued Liabilities Disclosure [Text Block]	6. Accrued Liabilities March 31, 2016 December 31, 2015 Accrued clinical trial expenses $ 1,042,050 $ 1,029,488 Accrued bonuses 254,425 723,039 Accrued salaries and vacation 194,438 202,059 Accrued drug manufacturing expenses 267,802 174,376 Interest payable 114,319 123,867 Accrued other 208,510 124,884 $ 2,081,544 $ 2,377,713

Other Liabilities

Other Liabilities	3 Months Ended
	Mar. 31, 2016
Other Liabilities Disclosure [Abstract]
Other Liabilities Disclosure [Text Block]	7. Other Liabilities March 31, 2016 December 31, 2015 Non-current income tax liability $ 991,654 $ 991,654 Deferred rent 32,523 35,339 $ 1,024,177 $ 1,026,993 In 2015, the Company completed a U.S. Federal and State of New Jersey Research and Development and U.S. Federal Orphan Drug tax credits analysis related to the years ended December 31, 2008 through 2014. The Company will claim the U.S. Federal Research and Development and Orphan Drug tax credits in the future on U.S. Federal tax returns. As a result, the Company will file amended New Jersey tax returns to report an income tax liability and interest which the Company recorded in 2015 as a non-current liability of $991,654 disclosed above.

Loans Payable

Loans Payable	3 Months Ended
	Mar. 31, 2016
Debt Disclosure [Abstract]
Debt Disclosure [Text Block]	8. Loans Payable On May 9, 2014, the Company entered into a term loan agreement for $ 15 10 5 10 9.75 Pursuant to the loan agreement, the Company issued Hercules a warrant to purchase an aggregate of 210,675 2.67 397,649 407,253 66,194 50,518 350,518 In addition, the Company will pay an end of term charge of $ 592,500 45,923 44,146 On April 25, 2016, the Company entered into an amendment agreement with Hercules which provided that the scheduled principal payments due on May 1, 2016 and the first business day of each month thereafter through and including the payment due on May 1, 2017 will be deferred (“deferred payments”). Commencing on June 1, 2017, and continuing on the first business day of each month thereafter, the Company will recommence scheduled payments of principal and interest based on original amortization period of thirty-one (31) consecutive months with a balloon payment of all the deferred payments included in the last installment. The deferred payments and all other accrued but unpaid interest will be due and payable on the loan maturity date of June 1, 2018. The current portion of debt on the consolidated balance sheet and the summary of payments disclosed below were adjusted for this amendment. March 31, 2016 December 31, 2015 Loan payable $ 13,275,698 $ 14,572,558 End of term fee 349,320 303,398 13,625,018 14,875,956 Deferred debt issuance costs (350,518) (416,712) 13,274,500 14,459,244 Less: Current portion (436,690) (5,378,134) Long-term debt $ 12,837,810 $ 9,081,110 2016 $ 436,690 2017 2,603,824 2018 10,827,684 Total loan payments 13,868,198 Less end of term fee (592,500) $ 13,275,698

Stockholders' Equity

Stockholders' Equity	3 Months Ended
	Mar. 31, 2016
Equity [Abstract]
Stockholders' Equity Note Disclosure [Text Block]	9. Stockholders’ Equity Public Offering of Common Stock On March 29, 2016, the Company completed a public offering of 4,600,000 600,000 9.50 43.7 40.6 At-The-Market Equity Offering Program On October 16, 2015, the Company entered into a Controlled Equity Offering Sales Agreement (the “Sales Agreement”) with Cantor Fitzgerald & Co. (“Cantor”) to sell shares of common stock with aggregate gross proceeds of up to $ 20.0 3.0 During the first quarter of 2016, the Company sold 1,353,900 7.43 10.1 9.8 7.9 Warrants During the first quarter of 2016, 321,384 2.99 85,170 12,445 11.25 . Issue date Number of Exercise price Term Expiry December 2011 123,585 $ 5.21 7 years December 2018 February 2012 3,700 $ 5.21 6 years February 2018 June 2012 17,267 $ 5.21 7 years June 2019 August 2012 112,536 $ 5.21 7 years August 2019 April 2013 159,806 $ 5.21 7 years April 2020 April 2013 3,934,649 $ 3.58 7 years April 2020 October 2014 807,777 $ 3.58 5 years October 2019 5,159,320

Stock Based Compensation

Stock Based Compensation	3 Months Ended
	Mar. 31, 2016
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Disclosure of Compensation Related Costs, Share-based Payments [Text Block]	10. Stock Based Compensation 2013 Equity Incentive Plan In 2013, the Company adopted the Celator Pharmaceuticals, Inc. 2013 Equity Incentive Plan (the “Plan”). Options granted under the Plan may be incentive stock options or non-qualified stock options. Incentive stock options may only be granted to employees. The board of directors, or a committee of the board of directors appointed to administer the Plan, determines the period over which options become exercisable and the conditions under which stock awards are granted and become vested. Weighted Weighted Average Number of Average Contractual Life Aggregate Outstanding at December 31, 2015 3,944,571 $ 2.90 Granted 1,599,024 1.32 Exercised (100,087) 2.25 Cancelled (5,334) 2.25 Outstanding at March 31, 2016 5,438,174 $ 2.45 8.1 $ 46,686,011 Exercisable at March 31, 2016 2,488,458 $ 2.73 7.1 $ 20,650,985 During the three months ended March 31, 2016, 12,081 shares were withheld to satisfy the exercise of certain stock options exercised during the period. In January 2016, the Company granted 397,024 stock options, included in the options granted above, to certain employees as payment of $365,262 of bonuses earned and accrued as of December 31, 2015. In February 2015, the Company issued 60,517 shares of common stock to certain Company employees as payment of $168,843 of bonuses earned and accrued as of December 31, 2014. Three months ended March 31 2016 2015 Stock compensation expense recognized $ 576,070 $ 359,200 Weighted average grant-date fair value of stock options issued (per share) $ 1.03 $ 2.31 Grant-date fair value of stock options issued $ 1,651,472 $ 1,360,094 Volatility 98.8 % 106.9 % Risk-free interest rate 1.7 % 1.7 % Dividend yield 0 % 0 % Expected life in years 5.9 6.2 Intrinsic value of stock options exercised $ 669,582 $ - The grant-date fair value of stock options is estimated using the Black Scholes option pricing model. The Company determined the options’ life based on the simplified method and determined the options’ expected volatility based on peer group volatility and dividend yield based on the historical dividend payments. The risk free interest rate is based on the yield of an applicable term Treasury instrument. The Company amortizes the fair value of the stock options on a straight-line basis over the applicable requisite service periods of the awards, which is generally the vesting period. At March 31, 2016, the total compensation cost related to non-vested awards not yet recognized and weighted average period over which it will be recognized was $ 4,850,285 2.5

Geographic Segment Information

Geographic Segment Information	3 Months Ended
	Mar. 31, 2016
Segment Reporting [Abstract]
Segment Reporting Disclosure [Text Block]	11. Geographic Segment Information The Company operates in the United States and Canada. The Company’s CPX-351 clinical trial materials are manufactured by a third party using the Company’s equipment located in Germany. Total Assets March 31, 2016 December 31, 2015 United States $ 68,531,389 $ 24,256,629 Canada 156,905 204,283 Germany 717,258 757,560 Total Assets $ 69,405,552 $ 25,218,472 Net Loss Three months ended March 31 2016 2015 United States $ (5,199,096) $ (4,311,341) Canada (334,227) (399,642) Total Net Loss $ (5,533,323) $ (4,710,983)

Commitments and Contingencies

Commitments and Contingencies	3 Months Ended
	Mar. 31, 2016
Commitments And Contingencies Disclosure [Abstract]
Commitments And Contingencies Disclosure [Text Block]	12. Commitments and Contingencies In September 2015, the Company entered into a lease agreement for office and laboratory space in Vancouver, British Columbia, which expires in August 2017. The remaining minimum lease payments as of March 31, 2016 were $ 159,700 In March 2013, the Company entered into an office lease agreement for office space in Ewing, New Jersey, which commenced in June 2013 with a term of sixty months. The remaining minimum lease payments as of March 31, 2016 were $ 322,000 200,000 120,000 The Company has a worldwide exclusive license agreement with Princeton University dated June 2007 that provides the Company with exclusive rights to some aspects of its nanoparticle polymer technology arising from research sponsored by the Company at Princeton University between 2003 and 2007. These inventions are generally characterized as particulate constructs for release of active agents for medical application. Of the products currently in the Company’s pipeline, only the hydrophobic docetaxel prodrug nanoparticle (HDPN) formulation is subject to this agreement. The Company is obligated to pay a royalty on net sales to Princeton University of a low single-digit percentage if any invention is sold by the Company or a company to which the product covered by the invention was licensed by the Company, which was generated under the exclusive licensing agreement. No royalty or other product/sub-license-related payments have been made to date. The Company is obligated to provide Princeton University a percentage within the range of 45 55 90 60 The Company has a collaborative research agreement dated May 2001 with the British Columbia Cancer Agency (“BCCA”) whereby in consideration for the license and conditional assignment of all Company-sponsored intellectual property to the Company by BCCA, the Company will pay to BCCA a royalty in the low single digits on net sales of royalty-bearing products in territories so long as a valid claim exists for inventions made between June 2000 and June 2005 under the agreement. All obligations relating to the conduct of the research and assignment of intellectual property have been completed. No payments of royalties have been made to date. Either party may terminate the agreement if the other party commits a material breach or default and such breach or default is not reasonably cured within 45 In consideration of funding by LLS and transfer to the Company of any rights LLS may have to any project inventions developed during the term of the agreement, the Company may be required to pay LLS a cash multiple on the LLS funding, (LLS funding is the $ 5 4.1 50 1.5 3.55 5

Summary of Significant Accoun19

Summary of Significant Accounting Policies (Policies)	3 Months Ended
	Mar. 31, 2016
Accounting Policies [Abstract]
Consolidation, Policy [Policy Text Block]	Basis of consolidation : The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries, Celator Pharmaceuticals Corp. (“CPC”) and Celator UK Ltd. All intercompany transactions have been eliminated.
Use of Estimates, Policy [Policy Text Block]	Use of estimates: The preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of expenses during the reporting period. Actual results may differ from those estimates. Significant areas requiring management estimates in the preparation of these consolidated financial statements include, amongst other things, assessment of other receivables, accrued liabilities, impairment and amortization of property and equipment, valuation allowance for deferred income taxes, valuation of stock-based compensation and contingencies.
New Accounting Pronouncements, Policy [Policy Text Block]	New Accounting Pronouncements Adopted: Deferred As Reported Financing Costs Adjusted December 31, 2015 Reclassification December 31, 2015 Assets Other assets $ 460,710 $ (416,712) $ 43,998 Total assets $ 25,635,184 $ (416,712) $ 25,218,472 Loans payable $ 9,497,822 $ (416,712) $ 9,081,110 Total liabilities 19,104,271 (416,712) 18,687,559 Total liabilities and stockholders' equity $ 25,635,184 $ (416,712) $ 25,218,472 All other new guidance that became effective during the reported period did not have a material impact on the Company’s consolidated financial statements. In February 2016, the FASB issued comprehensive new guidance about leases. Under the new guidance, most leases will be recognized on an entity’s balance sheet as liabilities with corresponding right-of-use assets. The new guidance is effective for interim and annual period in fiscal years beginning after December 15, 2018, with early adoption permitted. The standard must be adopted using a modified retrospective approach. We have not yet evaluated the impact of this new pronouncement. In November 2015, the FASB issued guidance which requires entities with a classified balance sheet to present all deferred tax assets and liabilities as noncurrent. The guidance is effective for public business entities for interim and annual periods in fiscal years beginning after December 15, 2016. This guidance is not expected to have a material impact on the Company’s consolidated financial position, results of operations or cash flows. In August 2014, the FASB issued guidance on management’s responsibility in evaluating whether there is substantial doubt about a company’s ability to continue as a going concern and about related footnote disclosures. For each reporting period, management will be required to evaluate whether there are conditions or events that raise substantial doubt about a company’s ability to continue as a going concern within one year from the date the financial statements are issued. The guidance is effective for the annual period ending after December 15, 2016, and for annual periods and interim periods thereafter.

Summary of Significant Accoun20

Summary of Significant Accounting Policies (Tables)	3 Months Ended
	Mar. 31, 2016
Accounting Policies [Abstract]
Schedule of New Accounting Pronouncements and Changes in Accounting Principles [Table Text Block]	The following table summarizes the cumulative effect of the change on total assets, total liabilities and stockholders’ equity in the statement of financial position as of the beginning of the period presented. The adoption of the guidance did not have any effect on loss from operations, and loss per share amounts for the current period and any prior periods. Deferred As Reported Financing Costs Adjusted December 31, 2015 Reclassification December 31, 2015 Assets Other assets $ 460,710 $ (416,712) $ 43,998 Total assets $ 25,635,184 $ (416,712) $ 25,218,472 Loans payable $ 9,497,822 $ (416,712) $ 9,081,110 Total liabilities 19,104,271 (416,712) 18,687,559 Total liabilities and stockholders' equity $ 25,635,184 $ (416,712) $ 25,218,472

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	3 Months Ended
	Mar. 31, 2016
Fair Value Disclosures [Abstract]
Fair Value, by Balance Sheet Grouping [Table Text Block]	The Company recognizes transfers between input levels as of the actual date of event. Fair Value (Level 1) (Level 2) (Level 3) March 31, 2016 Assets: Money Market Fund $ 17,194,140 $ 17,194,140 $ - $ - December 31, 2015 Assets: Money Market Fund $ 22,162,678 $ 22,162,678 $ - $ -

Other Current Assets (Tables)

Other Current Assets (Tables)	3 Months Ended
	Mar. 31, 2016
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
Schedule of Other Current Assets [Table Text Block]	Other current assets as of March 31, 2016 and December 31, 2015, consist of the following: March 31, 2016 December 31, 2015 Clinical trial materials $ 407,043 $ 414,904

Property and Equipment (Tables)

Property and Equipment (Tables)	3 Months Ended
	Mar. 31, 2016
Property Plant And Equipment [Abstract]
Property, Plant and Equipment [Table Text Block]	Property and equipment as of March 31, 2016 and December 31, 2015, including assets held under capital lease, consists of the following: March 31, 2016 December 31, 2015 Computer and equipment $ 118,935 $ 117,135 Furniture and office equipment 73,863 73,863 Laboratory equipment 1,754,608 1,754,608 Capital lease equipment 155,524 155,524 Leaseholds 56,227 54,732 2,159,157 2,155,862 Less: Accumulated depreciation (1,342,719) (1,294,372) $ 816,438 $ 861,490

Accrued Liabilities (Tables)

Accrued Liabilities (Tables)	3 Months Ended
	Mar. 31, 2016
Payables And Accruals [Abstract]
Schedule of Accrued Liabilities [Table Text Block]	Accrued liabilities as of March 31, 2016 and December 31, 2015 consist of the following: March 31, 2016 December 31, 2015 Accrued clinical trial expenses $ 1,042,050 $ 1,029,488 Accrued bonuses 254,425 723,039 Accrued salaries and vacation 194,438 202,059 Accrued drug manufacturing expenses 267,802 174,376 Interest payable 114,319 123,867 Accrued other 208,510 124,884 $ 2,081,544 $ 2,377,713

Other Liabilities (Tables)

Other Liabilities (Tables)	3 Months Ended
	Mar. 31, 2016
Other Liabilities Disclosure [Abstract]
Other Noncurrent Liabilities [Table Text Block]	Other non-current liabilities as of March 31, 2016 and December 31, 2015 consist of the following: March 31, 2016 December 31, 2015 Non-current income tax liability $ 991,654 $ 991,654 Deferred rent 32,523 35,339 $ 1,024,177 $ 1,026,993

Loans Payable (Tables)

Loans Payable (Tables)	3 Months Ended
	Mar. 31, 2016
Debt Disclosure [Abstract]
Schedule of Debt [Table Text Block]	Long-term debt as of March 31, 2016 and December 31, 2015, consists of the following: March 31, 2016 December 31, 2015 Loan payable $ 13,275,698 $ 14,572,558 End of term fee 349,320 303,398 13,625,018 14,875,956 Deferred debt issuance costs (350,518) (416,712) 13,274,500 14,459,244 Less: Current portion (436,690) (5,378,134) Long-term debt $ 12,837,810 $ 9,081,110
Schedule of Maturities of Long-term Debt [Table Text Block]	The summary of payments due on the term loan as of March 31, 2016, is as follows: 2016 $ 436,690 2017 2,603,824 2018 10,827,684 Total loan payments 13,868,198 Less end of term fee (592,500) $ 13,275,698

Stockholders' Equity (Tables)

Stockholders' Equity (Tables)	3 Months Ended
	Mar. 31, 2016
Equity [Abstract]
Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]	The following table summarizes the warrants outstanding to purchase common stock at March 31, 2016: Issue date Number of Exercise price Term Expiry December 2011 123,585 $ 5.21 7 years December 2018 February 2012 3,700 $ 5.21 6 years February 2018 June 2012 17,267 $ 5.21 7 years June 2019 August 2012 112,536 $ 5.21 7 years August 2019 April 2013 159,806 $ 5.21 7 years April 2020 April 2013 3,934,649 $ 3.58 7 years April 2020 October 2014 807,777 $ 3.58 5 years October 2019 5,159,320

Stock Based Compensation (Table

Stock Based Compensation (Tables)	3 Months Ended
	Mar. 31, 2016
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]	The following table summarizes the activity of the Company’s stock option plans for the three months ended March 31, 2016: Weighted Weighted Average Number of Average Contractual Life Aggregate Outstanding at December 31, 2015 3,944,571 $ 2.90 Granted 1,599,024 1.32 Exercised (100,087) 2.25 Cancelled (5,334) 2.25 Outstanding at March 31, 2016 5,438,174 $ 2.45 8.1 $ 46,686,011 Exercisable at March 31, 2016 2,488,458 $ 2.73 7.1 $ 20,650,985
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]	The following table provides information regarding stock options activity for the three months ended March 31, 2016 and 2015: Three months ended March 31 2016 2015 Stock compensation expense recognized $ 576,070 $ 359,200 Weighted average grant-date fair value of stock options issued (per share) $ 1.03 $ 2.31 Grant-date fair value of stock options issued $ 1,651,472 $ 1,360,094 Volatility 98.8 % 106.9 % Risk-free interest rate 1.7 % 1.7 % Dividend yield 0 % 0 % Expected life in years 5.9 6.2 Intrinsic value of stock options exercised $ 669,582 $ -

Geographic Segment Information

Geographic Segment Information (Tables)	3 Months Ended
	Mar. 31, 2016
Segment Reporting [Abstract]
Schedule of Segment Reporting Information, by Segment [Table Text Block]	Geographic net loss information is based on the location whereby the expenses were incurred. The geographic information about total assets is based on the physical location of the assets. Total Assets March 31, 2016 December 31, 2015 United States $ 68,531,389 $ 24,256,629 Canada 156,905 204,283 Germany 717,258 757,560 Total Assets $ 69,405,552 $ 25,218,472 Net Loss Three months ended March 31 2016 2015 United States $ (5,199,096) $ (4,311,341) Canada (334,227) (399,642) Total Net Loss $ (5,533,323) $ (4,710,983)

Nature of Business and Liquid30

Nature of Business and Liquidity (Details Textual) - USD ($)	Mar. 31, 2016	Dec. 31, 2015	Mar. 31, 2015	Dec. 31, 2014
Nature Of Business And Liquidity [Line Items]
Accumulated deficit	$ (174,216,924)	$ (168,683,601)
Cash and Cash Equivalents, at Carrying Value	$ 67,541,467	$ 23,253,328	$ 32,897,812	$ 32,413,777

Summary of Significant Accoun31

Summary of Significant Accounting Policies (Details) - USD ($)	Mar. 31, 2016	Dec. 31, 2015
Assets
Other assets	$ 43,024	$ 43,998
Total assets	69,405,552	25,218,472
Loans payable	12,837,810	9,081,110
Total liabilities	16,774,590	18,687,559
Total liabilities and stockholders' equity	$ 69,405,552	25,218,472
Scenario, Previously Reported [Member]
Assets
Other assets		460,710
Total assets		25,635,184
Loans payable		9,497,822
Total liabilities		19,104,271
Total liabilities and stockholders' equity		25,635,184
Restatement Adjustment [Member]
Assets
Other assets		(416,712)
Total assets		(416,712)
Loans payable		(416,712)
Total liabilities		(416,712)
Total liabilities and stockholders' equity		$ (416,712)

Fair Value Measurements (Detail

Fair Value Measurements (Details) - USD ($)	Mar. 31, 2016	Dec. 31, 2015
Assets:
Money Market Fund	$ 17,194,140	$ 22,162,678
Fair Value, Inputs, Level 1 [Member]
Assets:
Money Market Fund	17,194,140	22,162,678
Fair Value, Inputs, Level 2 [Member]
Assets:
Money Market Fund	0	0
Fair Value, Inputs, Level 3 [Member]
Assets:
Money Market Fund	$ 0	$ 0

Other Current Assets (Details)

Other Current Assets (Details) - USD ($)	Mar. 31, 2016	Dec. 31, 2015
Other Current Assets [Line Items]
Clinical trial materials	$ 407,043	$ 414,904

Property and Equipment (Details

Property and Equipment (Details) - USD ($)	Mar. 31, 2016	Dec. 31, 2015
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$ 2,159,157	$ 2,155,862
Less: Accumulated depreciation	(1,342,719)	(1,294,372)
Property and equipment, net	816,438	861,490
Computer and equipment [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	118,935	117,135
Furniture and office equipment [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	73,863	73,863
Laboratory equipment [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	1,754,608	1,754,608
Capital lease equipment [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	155,524	155,524
Leaseholds [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$ 56,227	$ 54,732

Property and Equipment (Detai35

Property and Equipment (Details Textual) - USD ($)	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Property, Plant and Equipment [Line Items]
Depreciation And Amortization	$ 48,347	$ 48,928

Accrued Liabilities (Details)

Accrued Liabilities (Details) - USD ($)	Mar. 31, 2016	Dec. 31, 2015
Accrued Liabilities [Line Items]
Accrued clinical trial expenses	$ 1,042,050	$ 1,029,488
Accrued bonuses	254,425	723,039
Accrued salaries and vacation	194,438	202,059
Accrued drug manufacturing expenses	267,802	174,376
Interest payable	114,319	123,867
Accrued other	208,510	124,884
Accrued liabilities	$ 2,081,544	$ 2,377,713

Other Liabilities (Details)

Other Liabilities (Details) - USD ($)	Mar. 31, 2016	Dec. 31, 2015
Other Non Current Liabilities [Line Items]
Non-current income tax liability	$ 991,654	$ 991,654
Deferred rent	32,523	35,339
Other non-current liabilities	$ 1,024,177	$ 1,026,993

Loans Payable (Details)

Loans Payable (Details) - USD ($)	Mar. 31, 2016	Dec. 31, 2015
Debt Instrument [Line Items]
Loan payable	$ 13,275,698	$ 14,572,558
End of term fee	349,320	303,398
Long-term Debt, Gross	13,625,018	14,875,956
Deferred debt issuance costs	(350,518)	(416,712)
Total loan payments	13,274,500	14,459,244
Less: Current portion	(436,690)	(5,378,134)
Long-term debt	$ 12,837,810	$ 9,081,110

Loans Payable (Details 1)

Loans Payable (Details 1)	Mar. 31, 2016USD ($)
Debt Instrument [Line Items]
2,016	$ 436,690
2,017	2,603,824
2,018	10,827,684
Total loan payments	13,868,198
Less end of term fee	(592,500)
Long-term debt	$ 13,275,698

Loans Payable (Details Textual)

Loans Payable (Details Textual) - USD ($)	May. 09, 2014	Mar. 30, 2015	Mar. 31, 2016	Mar. 31, 2015
Debt Instrument [Line Items]
Amortization Of Financing Costs And Discounts			$ 112,117	$ 94,664
Proceeds From Issuance Of Debt			$ 0	$ 5,000,000
Hercules Technology Growth Capital [Member]
Debt Instrument [Line Items]
Line of Credit Facility, Fair Value of Amount Outstanding	$ 10,000,000
Line of Credit Facility, Maximum Borrowing Capacity	$ 15,000,000
Long-term Debt, Maturities, Repayment Terms	repayable in installments over forty-eight months and, at drawdown date, had an interest-only period of eighteen months after closing
Line of Credit Facility, Interest Rate Description	Interest is payable monthly at the greater of 9.75% or an adjusted rate based upon the U.S. prime rate with interest only period until December 1, 2015.
Line of Credit Facility, Interest Rate During Period			10.00%	9.75%
Proceeds From Issuance Of Debt		$ 5,000,000
Hercules Technology Growth Capital [Member] | Term Loan [Member]
Debt Instrument [Line Items]
Amortization Of Financing Costs And Discounts			$ 66,194	$ 50,518
Deferred Finance Costs, Noncurrent, Net			$ 350,518
Hercules Technology Growth Capital [Member] | Warrant [Member]
Debt Instrument [Line Items]
Stock Issued During Period, Shares, New Issues			210,675
Class of Warrant or Right, Exercise Price of Warrants or Rights			$ 2.67
Debt Issuance Cost			$ 397,649
Warrants Maturity Term			5 years
Hercules Technology Growth Capital [Member] | Term Loans [Member]
Debt Instrument [Line Items]
Debt Issuance Cost			$ 407,253
Hercules Technology Growth Capital [Member] | End of Term Fees [Member]
Debt Instrument [Line Items]
Amortization Of Financing Costs And Discounts			45,923	$ 44,146
Debt Issuance Cost			$ 592,500

Stockholders' Equity (Details)

Stockholders' Equity (Details)	3 Months Ended
	Mar. 31, 2016$ / sharesshares
Class of Warrant or Right, Outstanding	5,159,320
December 2011 [Member]
Class of Warrant or Right, Outstanding	123,585
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares	$ 5.21
Warrants Maturity Term	7 years
Warrants Expiry Period	December2018
February 2012 [Member]
Class of Warrant or Right, Outstanding	3,700
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares	$ 5.21
Warrants Maturity Term	6 years
Warrants Expiry Period	February2018
June 2012 [Member]
Class of Warrant or Right, Outstanding	17,267
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares	$ 5.21
Warrants Maturity Term	7 years
Warrants Expiry Period	June 2,019
August 2012 [Member]
Class of Warrant or Right, Outstanding	112,536
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares	$ 5.21
Warrants Maturity Term	7 years
Warrants Expiry Period	August2019
April 2013 [Member]
Class of Warrant or Right, Outstanding	159,806
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares	$ 5.21
Warrants Maturity Term	7 years
Warrants Expiry Period	April2020
April 2013 One [Member]
Class of Warrant or Right, Outstanding	3,934,649
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares	$ 3.58
Warrants Maturity Term	7 years
Warrants Expiry Period	April2020
October 2014 [Member]
Class of Warrant or Right, Outstanding	807,777
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares	$ 3.58
Warrants Maturity Term	5 years
Warrants Expiry Period	October2019

Stockholders' Equity (Details T

Stockholders' Equity (Details Textual) - USD ($)	1 Months Ended		3 Months Ended
	Mar. 29, 2016	Oct. 16, 2015	Mar. 31, 2016	Mar. 31, 2015
Schedule Of Shareholders Equity [Line Items]
Stock Issued During Period, Value, New Issues			$ 50,396,400
Proceeds From Issuance Of Common Stock			$ 51,105,723	$ 0
Class of Warrants, Exercises in Period			321,384
Class of Warrants, Expired in Period, Weighted Average Exercise Price			$ 11.25
Class of Warrants, Expired in Period			12,445
Warrants Or Rights Exercises In Period Weighted Average Exercise Price			$ 2.99
Common Stock [Member]
Schedule Of Shareholders Equity [Line Items]
Stock Issued During Period, Value, New Issues			$ 5,954
Stock Issued During Period, Shares, New Issues			5,953,900
Warrant [Member]
Schedule Of Shareholders Equity [Line Items]
Stock Issued During Period, Value, New Issues			$ 0
Shares Withheld To Satisfy Exercise Of Certain Warrants Exercised			85,170
Controlled Equity Offering Sales Agreement [Member]
Schedule Of Shareholders Equity [Line Items]
Stock Issued During Period, Value, New Issues			$ 10,100,000
Commission Percentage On Gross Proceeds		3.00%
Stock Issued During Period, Shares, New Issues			1,353,900
Shares Issued, Price Per Share			$ 7.43
Proceeds From Issuance Of Common Stock			$ 9,800,000
Maximum Common Stock Available To Be Sold		$ 20,000,000
Remaining Common Stock Available To Be Sold			$ 7,900,000
Public Offering [Member]
Schedule Of Shareholders Equity [Line Items]
Proceeds From Issuance Of Common Stock	$ 40,600,000
Public Offering [Member] | Common Stock [Member]
Schedule Of Shareholders Equity [Line Items]
Stock Issued During Period, Value, New Issues	$ 43,700,000
Stock Issued During Period, Shares, New Issues	4,600,000
Shares Issued, Price Per Share	$ 9.50
Public Offering [Member] | Common Stock [Member] | Over-Allotment Option [Member]
Schedule Of Shareholders Equity [Line Items]
Stock Issued During Period, Shares, New Issues	600,000

Stock Based Compensation (Detai

Stock Based Compensation (Details) - Stock Option [Member]	3 Months Ended
	Mar. 31, 2016USD ($)$ / sharesshares
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of options, Beginning balance | shares	3,944,571
Number of options, Granted | shares	1,599,024
Number of options, Exercised | shares	(100,087)
Number of options, Cancelled | shares	(5,334)
Number of options, Ending balance | shares	5,438,174
Number of options, Exercisable | shares	2,488,458
Weighted Average Exercise price, Beginning balance (in dollars per share) | $ / shares	$ 2.90
Weighted Average Exercise price, Granted (in dollars per share) | $ / shares	1.32
Weighted Average Exercise price, Exercised (in dollars per share) | $ / shares	2.25
Weighted Average Exercise price, Cancelled (in dollars per share) | $ / shares	2.25
Weighted Average Exercise price, Ending balance (in dollars per share) | $ / shares	2.45
Weighted Average Exercise price, Exercisable (in dollars per share) | $ / shares	$ 2.73
Weighted Average Remaining Contractual Life (Yrs), Outstanding (in years)	8 years 1 month 6 days
Weighted Average Remaining Contractual Life (Yrs), Exercisable (in years)	7 years 1 month 6 days
Aggregate Intrinsic Value, outstanding (in dollars) | $	$ 46,686,011
Aggregate Intrinsic Value, Exercisable (in dollars) | $	$ 20,650,985

Stock Based Compensation (Det44

Stock Based Compensation (Details 1) - USD ($)	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock compensation expense recognized	$ 576,070	$ 359,200
Weighted average grant-date fair value of stock options issued (per share)	$ 1.03	$ 2.31
Grant-date fair value of stock options issued	$ 1,651,472	$ 1,360,094
Volatility	98.80%	106.90%
Risk-free interest rate	1.70%	1.70%
Dividend yield	0.00%	0.00%
Expected life in years	5 years 10 months 24 days	6 years 2 months 12 days
Intrinsic value of stock options exercised	$ 669,582	$ 0

Stock Based Compensation (Det45

Stock Based Compensation (Details Textual) - USD ($)	3 Months Ended	12 Months Ended
	Mar. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock Issued During Period, Shares, Share-based Compensation, Net of Forfeitures, Total		397,024	60,517
Stock Issued During Period, Value, Share-based Compensation, Net of Forfeitures, Total	$ 365,262	$ 365,262	$ 168,843
Shares Withheld to Satisfy Exercise of Certain Stock Options Exercised	12,081
Non vested Awards [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options	$ 4,850,285
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition	2 years 6 months

Geographic Segment Informatio46

Geographic Segment Information (Details) - USD ($)	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015	Dec. 31, 2015
Revenues from External Customers and Long-Lived Assets [Line Items]
Total Assets	$ 69,405,552		$ 25,218,472
Total Net Loss	(5,533,323)	$ (4,710,983)
United States
Revenues from External Customers and Long-Lived Assets [Line Items]
Total Assets	68,531,389		24,256,629
Total Net Loss	(5,199,096)	(4,311,341)
Canada
Revenues from External Customers and Long-Lived Assets [Line Items]
Total Assets	156,905		204,283
Total Net Loss	(334,227)	$ (399,642)
Germany
Revenues from External Customers and Long-Lived Assets [Line Items]
Total Assets	$ 717,258		$ 757,560

Commitments and Contingencies (

Commitments and Contingencies (Details Textual) - USD ($)	3 Months Ended
	Mar. 31, 2016	Jun. 30, 2013
Loss Contingencies [Line Items]
Restricted Investments	$ 120,000
Princeton University Agreement [Member]
Loss Contingencies [Line Items]
Agreement termination notice period	90 days
Rectification of default period	60 days
Leukemia & Lymphoma Society Agreement [Member]
Loss Contingencies [Line Items]
Percentage of royalty payable from the amount received from out-licenses and transfers	50.00%
Leukemia & Lymphoma Society Agreement [Member] | Phase 3 study [Member]
Loss Contingencies [Line Items]
Funding for project inventions	$ 5,000,000
Leukemia & Lymphoma Society Agreement [Member] | Phase 2 study [Member]
Loss Contingencies [Line Items]
Funding for project inventions	4,100,000
Vancouver Laboratory Space, British Columbia [Member]
Loss Contingencies [Line Items]
Operating Leases, Future Minimum Payments Due, Total	159,700
Ewing, New Jersey [Member]
Loss Contingencies [Line Items]
Operating Leases, Future Minimum Payments Due, Total	$ 322,000
Letters of Credit Outstanding, Amount		$ 200,000
British Columbia Cancer Agency [Member]
Loss Contingencies [Line Items]
Rectification of default period	45 days
Minimum [Member] | Princeton University Agreement [Member]
Loss Contingencies [Line Items]
Percentage of royalty payable from the amount received from out-licenses and transfers	45.00%
Minimum [Member] | Leukemia & Lymphoma Society Agreement [Member]
Loss Contingencies [Line Items]
Number of times amount payable under research funding program	1.5
Maximum [Member] | Princeton University Agreement [Member]
Loss Contingencies [Line Items]
Percentage of royalty payable from the amount received from out-licenses and transfers	55.00%
Maximum [Member] | Leukemia & Lymphoma Society Agreement [Member]
Loss Contingencies [Line Items]
Number of times amount payable under research funding program	3.55
Percentage Of Cash Payment Or Loyalties	5.00%